Mycophenolate Use in Reproductive-Aged Patients: What Every Osteopathic Clinician Should Know

CME Search

Mycophenolate Use in Reproductive-Aged Patients: What Every Osteopathic Clinician Should Know

On-Demand

There is a critical and well-documented gap in clinician awareness and patient counseling regarding the embryofetal toxicity risks associated with mycophenolate use during pregnancy. Despite established evidence linking prenatal exposure to significantly increased risks of first trimester pregnancy loss and congenital malformations, current clinical practices often lack consistent implementation of risk mitigation strategies. This gap compromises patient safety, particularly among reproductive-age individuals who may not receive adequate counseling on pregnancy prevention or informed decision-making prior to initiating therapy. This interactive, case-based activity will target awareness, counseling protocols and risk mitigation.

Learning objectives

After completing this activity, learners will be able to:

Recognize the increased risks of first trimester pregnancy loss and congenital malformations associated with mycophenolate use.
Explain the risks of mycophenolate exposure during pregnancy to patients.
Demonstrate effective patient education on pregnancy prevention, including appropriate contraceptive methods during treatment.
Identify alternative immunosuppressive therapies with lower embryofetal risk for use in pregnancy or preconception planning.
Describe the process for reporting pregnancies to the Mycophenolate Pregnancy Registry, per REMS requirements.
Review approaches to encourage patient participation in the registry to contribute to safety monitoring and research.

Activity Sponsor

American College of Osteopathic Internists

Anticipated Credits

1.5 AOA Category 1-B

Specialties

General

Topics

Women’s Health

Additional Details

Presented by Corinna Muller, DO, FACOOG (dist.), and Emmie Strassberg, DO, FACOOG (dist.)